Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
株式のランク
#3772
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
株価
$4.87
時価総額
$4.36B
変化（1日）
-5.47%
変化（1年）
-15.62%
国
CN
取引 Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
カテゴリー
Healthcare
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd（688336）の発行済株式数
October 2026 時点の発行済株式数 0
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd の最新の財務報告および株価によると、現在の発行済株式数は 0 です。October 2026 の終わりには、同社は 0 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd（688336）の発行済株式数の履歴（2006 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2025 | 617.38M | -0.11% |
| 2024 | 618.05M | 0.70% |
| 2023 | 613.78M | -0.40% |
| 2022 | 616.22M | 2.37% |
| 2021 | 601.95M | 2.42% |
| 2020 | 587.73M | 10.22% |
| 2019 | 533.24M | 4.51% |
| 2018 | 510.22M | 0.00% |
| 2017 | 510.22M | 0.86% |
| 2016 | 505.85M | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | -100.00% |
| 2012 | 508.39M | -1.58% |
| 2011 | 516.57M | 8.92% |
| 2010 | 474.28M | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| 0.00 | - |
BE
|
|
| 62.19M | - |
NL
|
